Lifebit's precision medicine software will power Hong Kong's development of 
genomic medicine by supporting the Hong Kong Genome Institute to implement the 
first large-scale genome sequencing initiative, the Hong Kong Genome Project. 
The Project will empower medical professionals and researchers to leverage up 
to 50,000 whole genomes to achieve faster diagnosis, more precise and 
personalised treatments and perform disease surveillance. 


The leader in precision medicine technology, Lifebit Biotech Ltd, today 
announced it has been awarded a four-year contract by Hong Kong Genome 
Institute (HKGI) to support its implementation of the first large-scale genome 
sequencing initiative in Hong Kong.

Lifebit offers federated solutions for leading precision medicine initiatives. 
In 2020, Lifebit and Genomics England launched a Trusted Research Environment [ 
https://www.genomicsengland.co.uk/research-environment-covid-19-lifebit-aws/ 
]which provides top pharma companies, researchers and clinicians secure and 
full-fledged analysis access to cancer and rare disease clinico-genomic data.

Funded by the Hong Kong SAR Government [ 
https://www.info.gov.hk/gia/general/202005/14/P2020051400636.htm ], HKGI is 
tasked to take forward the implementation of the Project with the view of 
serving as a catalyst to establish a genome database of local population, 
testing infrastructure and talent pool in Hong Kong. All of these will greatly 
facilitate the clinical application of genomic medicine and scientific 
research, and benefit patients and their families. To support HKGI and the 
Project, Lifebit will deploy a highly scalable cloud and HPC infrastructure to 
transform raw sequencing data into clinical diagnosis and research insights in 
as little as 3 hours.

Thorben Seeger, Lifebit VP Commercial, said:
"Precision medicine requires vast amounts of data to be analysed and we believe 
federated analysis will play a key role in powering the Project for HKGI. This 
federated approach is tremendously increasing researchers' access to diverse 
population genomics data worldwide, without putting sensitive patient data at 
risk, as the data will always remain secure in each initiative's own 
environment."

For the full release, click here [ 
https://blog.lifebit.ai/2021/05/25/hong-kongs-genome-lifebit/ ].

About Lifebit
To cure diseases, researchers need to access and use as much biomedical data as 
possible, which are often inaccessible and unusable. Lifebit's patented 
federated technology securely unlocks access to data-generating insights and 
delivers more precise drugs faster. From providing Trusted Research 
Environments for national precision medicine programmes to enabling 
pharmaceutical companies to discover new drug targets, Lifebit empowers 
customers across the public and private sectors to transform how they use 
sensitive biomedical data. 

Photo - https://mma.prnewswire.com/media/1516831/Lifebit_HK_Genome_Project.jpg 

Source: Lifebit Internal / Commercial Team